Author(s):
S.D. Mankar, R.S. Daud, S.S. Siddheshwar, M.P. Mhaske
Email(s):
sdmankar655@gmail.com
DOI:
10.52711/0974-360X.2025.00501 
Address:
S.D. Mankar*, R.S. Daud, S.S. Siddheshwar, M.P. Mhaske
Department of Pharmaceutics, Pravara Rural College of Pharmacy, Savitribai Phule Pune University, Pune 411038, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 8,
Year - 2025
ABSTRACT:
Nifedipine, a potent calcium-channel blocker which is use in treatment of hypertension belonging from BCS class II with poor solubility and bioavailability. The present investigational study purpose was to improve nifedipine solubility with help of liquisolid system. Nifedipine was dissolved in a appropriate non-volatile solvent (Transcutol) to make uniform suspension which was further mixed with various carriers (Avicel Ph 102, neusilin, fujicalin), coating material (Syloid) creating admixture with a free-flowing and direct compressible. Six batches were prepared using different loading factor (Lf) and carrier coating factor (R) 20. The optimised batch was selected based upon the % drug release. Liquisolid compact tablet was prepared by direct compression. FTIR analysis was used to confirm the drug-excipient interaction. A dissolution study was conducted on prepared liquisolid tablets and it was found that the formulation batch F-2 has shown optimum dissolution of nifedipine. The batches prepared were evaluated for the disintegration time, dissolution, hardness, friability, DSC, XDR. The optimised batch was showing higher percentage of drug dissolution.
Cite this article:
S.D. Mankar, R.S. Daud, S.S. Siddheshwar, M.P. Mhaske. Enhancing Nifedipine Dissolution through Liquisolid System: Formulation, Optimisation and Evaluation. Research Journal Pharmacy and Technology. 2025;18(8):3480-6. doi: 10.52711/0974-360X.2025.00501
Cite(Electronic):
S.D. Mankar, R.S. Daud, S.S. Siddheshwar, M.P. Mhaske. Enhancing Nifedipine Dissolution through Liquisolid System: Formulation, Optimisation and Evaluation. Research Journal Pharmacy and Technology. 2025;18(8):3480-6. doi: 10.52711/0974-360X.2025.00501 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-4
REFERENCES:
1. Khames, A. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. Drug Delivery. 2017; 24(1): 328-338. https://doi.org/10.1080/10717544.2016.1250140
2. Paradkar, A. R., Bakliwal, S. Biopharmaceutics and Pharmacokinetics. (3rd edn).
3. Sayyad, F. J., Tulsankar, S. L., Kolap, U. B. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. Journal of Pharmacy Research. 2013; 7(5): 381-388. https://doi.org/10.1016/j.jopr.2013.05.012
4. Sharma, D., Soni, M., Kumar, S., Gupta, G. D. Solubility enhancement: eminent role in poorly soluble drugs. Res J Pharm Tech. 2009; 2(2).
5. Löbenberg, R., Amidon, G. L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000; 50: 3-12. https://doi.org/10.1016/S0939-6411(00)00091-6
6. Tiong, N., Elkordy, A. A. Effects of liquisolid formulations on dissolution of naproxen. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 73(3): 373-384. https://doi.org/10.1016/j.ejpb.2009.08.002
7. Spireas, S. Liquisolid system and method of preparing same. U.S. Patent 6423339B1; 2002.
8. Spireas, S., inventor; Hygrosol Pharmaceutical CORP, assignee. Liquisolid systems and methods of preparing same. United States Patent US 6,423,339. 2002, July 23.
9. Jaydip, B., Dhaval, M., Soniwala, M. M., Chavda, J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharmaceutical Journal. 2020; 28(6): 737-745. https://doi.org/10.1016/j.jsps.2020.04.016